Stay updated with breaking news from Eric Dobmeier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) has been assigned a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last […]
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development...
Allspring Global Investments Holdings LLC bought a new stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,310 shares of the company’s stock, valued at approximately $65,000. Several other […]
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and...
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) CEO Eric Dobmeier purchased 5,000 shares of the stock in a transaction on Wednesday, May 25th. The shares were purchased at an average cost of $13.03 per share, for a total transaction of $65,150.00. Following the acquisition, the chief executive officer now directly owns 205,880 shares of the […]